📢 #Gate Square Writing Contest Phase 3# is officially kicks off!
🎮 This round focuses on: Yooldo Games (ESPORTS)
✍️ Share your unique insights and join promotional interactions. To be eligible for any reward, you must also participate in Gate’s Phase 286 Launchpool, CandyDrop, or Alpha activities!
💡 Content creation + airdrop participation = double points. You could be the grand prize winner!
💰Total prize pool: 4,464 $ESPORTS
🏆 First Prize (1 winner): 964 tokens
🥈 Second Prize (5 winners): 400 tokens each
🥉 Third Prize (10 winners): 150 tokens each
🚀 How to participate:
1️⃣ Publish an
Lyon: Remains optimistic about the development of Stone Pharmaceutical Group, maintaining a "highly confident outperform the market" rating.
Jin10 data reported on May 30 that Lyon published a research report indicating that although the sales of Enbipusi from Shanghai Pharmaceuticals (01093.HK) faced challenges, the first quarter performance still met expectations, with a year-on-year net profit fall of 8.4%. It is believed that Shanghai Pharmaceuticals' profits have bottomed out in the first quarter. In addition to the market's focus on SYS6010, the management also revealed that there are two other products that will achieve potential licensing cooperation, each exceeding $5 billion in scale. Lyon expressed continued optimism about Shanghai Pharmaceuticals' development, believing that its early R&D pipeline is competitive globally and has a differentiated innovative drug platform, maintaining a "highly confident outperform the market" rating for Shanghai Pharmaceuticals, with a target price of HKD 13.8.